A5023683463- Neuroscience and Neuropharmacology Research
- Receptor Mechanisms and Signaling
- Alzheimer's disease research and treatments
- Prion Diseases and Protein Misfolding
- Neuropeptides and Animal Physiology
- Genetic Neurodegenerative Diseases
- Functional Brain Connectivity Studies
- RNA and protein synthesis mechanisms
- Biotin and Related Studies
- Parkinson's Disease Mechanisms and Treatments
- Hormonal Regulation and Hypertension
- Heme Oxygenase-1 and Carbon Monoxide
- Tryptophan and brain disorders
- Computational Drug Discovery Methods
- Neuroinflammation and Neurodegeneration Mechanisms
- Nicotinic Acetylcholine Receptors Study
- Endoplasmic Reticulum Stress and Disease
- Cellular transport and secretion
- Cholesterol and Lipid Metabolism
- Monoclonal and Polyclonal Antibodies Research
- Redox biology and oxidative stress
Karolinska Institutet
2023-2024
University of Glasgow
2018-2022
Abstract INTRODUCTION Synaptic loss is an early prominent feature of Alzheimer's disease (AD). The recently developed novel synaptic vesicle 2A protein (SV2A) PET‐tracer UCB‐J has shown great promise in tracking AD. However, there have been discrepancies between the findings and a lack mechanistic insight. METHODS Here we report first extensive pre‐clinical validation studies for control (CN; n = 11) AD ( brains using multidimensional approach post‐mortem brain imaging techniques,...
Significance The M1 muscarinic acetylcholine receptor (M1-receptor) plays a crucial role in learning and memory is validated drug target for the treatment of Alzheimer’s disease (AD). Furthermore, M1-receptor ligands have been demonstrated to display disease-modifying effects preclinical models neurodegenerative disease. By employing genetic mouse model expressing G protein–biased combination with terminal disease, we demonstrate here that exerts an inherent neuroprotective activity...
Many dementias are propagated through the spread of "prion-like" misfolded proteins. This includes prion diseases themselves (such as Creutzfeldt-Jakob disease) and Alzheimer's disease (AD), for which no treatments available to slow or stop progression. The M
G protein‐coupled receptors (GPCRs) are a large family of cell surface that play critical role in nervous system function by transmitting signals between cells and their environment. They involved many, if not all, processes, dysfunction has been linked to various neurological disorders representing important drug targets. This overview emphasises the GPCRs system, which research focus members ERNEST COST action (CA18133) working group ‘Biological roles signal transduction’. First,...
The oxidation of methionine residues in proteins occurs during oxidative stress and can lead to an alteration protein function. enzyme sulfoxide reductase (Msr) reverses this modification. Here, we characterise the mammalian Msr B3. There are two splice variants that differ only their N-terminal signal sequence, which directs either endoplasmic reticulum (ER) or mitochondria. We demonstrate here complement a bacterial strain, is dependent on reduction for growth, purified recombinant...
Abstract INTRODUCTION Progressive supranuclear palsy (PSP) is a devastating 4R tauopathy affecting motor functions and often misdiagnosed/underdiagnosed due to lack of specific biomarkers. Synaptic loss an eminent feature tauopathies including PSP. Novel synaptic positron emission tomography tracer UCB‐J holds great potential for early diagnosis; however, there substantial knowledge gap in terms the mechanism extent nature METHODS Here, we report in‐depth post mortem validation mechanistic...
Abstract Background Synaptic loss is an eminent feature of tauopathies. The recently developed novel SV2A PET‐tracer UCB‐J has shown great promise in tracking synaptic However, there have been discrepancies between the vivo findings and a lack mechanistic insight. Many these studies indicated potential correlations tau deposition, atrophy, cognitive‐impairment, binding. Hence, we found it utmost relevance to perform extensive pre‐clinical validation tauopathic brains gain deeper...
ABSTRACT The most prevalent types of dementias, including Alzheimer’s disease, are those that propagated via the spread “prion-like” misfolded proteins. Despite considerable effort no treatments available to slow or stop progression these dementias. Here we investigate possibility activation M 1 -muscarinic receptor (M -receptor), which is highly expressed in brain and shows pro-cognitive properties, might present a novel disease modifying target. We demonstrate murine prion show here...
G protein-coupled receptors (GPCRs) are a large family of cell surface that play critical role in nervous system function by transmitting signals between cells and their environment. They involved many, if not all, processes, dysfunction has been linked to various neurological disorders representing important drug targets. In this review, we will first discuss the GPCRs modulation tripartite synapse how control energy metabolism brain. We then (patho)physiology pharmacology opioid,...
Abstract Background Progressive supranuclear palsy (PSP) is a 4R‐tauopathy causing problems with balance, movement, vision, speech, and swallowing. There lack of biomarkers for PSP, which often leads to misdiagnosis, prescription incorrect pharmacological treatments likely underdiagnosis. Synaptic vesicle protein 2A (SV2A) PET‐tracer UCB‐J has shown great promise in imaging synaptic loss many neurodegenerative diseases vivo including PSP. UCB‐J‐PET holds potential the early accurate...
Abstract Background Progressive supranuclear palsy (PSP) is a 4R‐tauopathy causing problems with balance, movement, vision, speech, and swallowing. There lack of biomarkers for PSP, which often leads to misdiagnosis, prescription incorrect pharmacological treatments likely underdiagnosis. Synaptic vesicle protein 2A (SV2A) PET‐tracer UCB‐J has shown great promise in imaging synaptic loss many neurodegenerative diseases vivo including PSP. UCB‐J‐PET holds potential the early accurate...
Abstract There are currently no treatments that can slow the progression of neurodegenerative diseases such as Alzheimer’s disease (AD). is, however, a growing body evidence activation M1 muscarinic acetylcholine receptor (M1-receptor) not only restore memory loss in AD patients, but preclinical animal models also progression. The generation an effective medicine targeting M1-receptor has however been severely hampered by associated cholinergic adverse responses. By using genetically...